Supernus Pharmaceuticals
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell SUPN and other ETFs, options, and stocks.About SUPN
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products.
CEOJack A. Khattar
CEOJack A. Khattar
Employees674
Employees674
HeadquartersRockville, Maryland
HeadquartersRockville, Maryland
Founded2005
Founded2005
Employees674
Employees674
SUPN Key Statistics
Market cap3.12B
Market cap3.12B
Price-Earnings ratio46.47
Price-Earnings ratio46.47
Dividend yield—
Dividend yield—
Average volume594.55K
Average volume594.55K
High today$55.95
High today$55.95
Low today$53.18
Low today$53.18
Open price$55.00
Open price$55.00
Volume2.12M
Volume2.12M
52 Week high$55.95
52 Week high$55.95
52 Week low$29.16
52 Week low$29.16
SUPN News
TipRanks 2d
Supernus Pharmaceuticals’ Real-World Study on ONAPGOTM: A Closer LookSupernus Pharmaceuticals ((SUPN)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at...
TipRanks 2d
Supernus Pharmaceuticals Advances ADHD Treatment Study in Young ChildrenSupernus Pharmaceuticals ((SUPN)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at...
Simply Wall St 6d
What Do Supernus’s Surging 2025 Returns Signal After Regulatory Progress?Thinking about what to do with your Supernus Pharmaceuticals shares? You’re not alone. With the stock closing recently at $52.02, investors are buzzing about it...
Analyst ratings
83%
of 6 ratingsBuy
83.3%
Hold
16.7%
Sell
0%
People also own
Based on the portfolios of people who own SUPN. This list is generated using Robinhood data, and it’s not a recommendation.